发明公开
EP2356133A2 RECOMBINANT PROTEIN BODIES AS IMMUNOGEN-SPECIFIC ADJUVANTS
审中-公开
重组蛋白体AS IMMUNOGENSPEZIFISCHE佐剂
- 专利标题: RECOMBINANT PROTEIN BODIES AS IMMUNOGEN-SPECIFIC ADJUVANTS
- 专利标题(中): 重组蛋白体AS IMMUNOGENSPEZIFISCHE佐剂
-
申请号: EP09740089.9申请日: 2009-10-09
-
公开(公告)号: EP2356133A2公开(公告)日: 2011-08-17
- 发明人: RYBICKI, Edwar, Peter , MEYERS, Ann, Elizabeth , DEVESA, François , MARZÁBAL LUNA, Pablo , HITZEROTH, Inga, Isabel , ÖHLSCHLÄGER, Peter
- 申请人: ERA Biotech, S.A.
- 申请人地址: Baldiri i Reixach 15/21 Parc Cientific de Barcelona 08028 Barcelona ES
- 专利权人: ERA Biotech, S.A.
- 当前专利权人: ERA Biotech, S.A.
- 当前专利权人地址: Baldiri i Reixach 15/21 Parc Cientific de Barcelona 08028 Barcelona ES
- 代理机构: ABG Patentes, S.L.
- 优先权: US104403P 20081010
- 国际公布: WO2010040847 20100415
- 主分类号: C07K14/025
- IPC分类号: C07K14/025 ; C07K14/425 ; C12N15/62 ; C07K14/16 ; A61K39/00
摘要:
An immunogen-specific is adjuvant for a vaccine or inoculum is disclosed. The adjuvant is comprised of particulate recombinant protein body-like assemblies (RPBLAs) that contain a recombinant fusion protein that contains two portions peptide-linked together. A first portion is a protein body-inducing sequence (PBIS) and a second portion is a T-cell stimulating immunogenic polypeptide whose sequence is that of a pathogenic polypeptide sequence present in or induced by a vaccine or inoculum. The adjuvant, when used as an inoculum in a host animal without a prior priming vaccination or inoculation, does not induce production of antibodies or T cell activation to the pathogenic sequence.
公开/授权文献
- EP2356133B1 RECOMBINANT PROTEIN BODIES AS IMMUNOGEN-SPECIFIC ADJUVANTS 公开/授权日:2019-07-31
信息查询